Extended Data Fig. 2: Five-year survival analysis per treatment arm for the confirmation-cohort OpACIN-neo. | Nature Medicine

Extended Data Fig. 2: Five-year survival analysis per treatment arm for the confirmation-cohort OpACIN-neo.

From: Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial

Extended Data Fig. 2

Patients in the OpACIN-neo trial were randomized to receive 2 cycles op ipilimumab (IPI) 3 mg kg−1 plus nivolumab (NIVO) 1 mg kg−1 in arm A (n = 30), 2 cycles of IPI 1 mg kg−1 plus NIVO 3 mg kg−1 in arm B (n = 30), or 2 cycles op IPI 3 mg kg−1 followed by NIVO 3 mg kg−1 in arm C (n = 26). a-e, Kaplan Meier curve including log-rank P value, sub grouped according to treatment-arm, for event free survival (a), relapse-free survival (b), distant metastases-free survival (c), overall survival (d), melanoma specific survival (from registration to melanoma related death) (e).

Back to article page